Jin-Tai Yu Selected Research

HLA-A*23 antigen

1/2017

HLA-A2 Alleles Mediate Alzheimer's Disease by Altering Hippocampal Volume.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jin-Tai Yu Research Topics

Disease

183	Alzheimer Disease (Alzheimer's Disease) 08/2022 - 02/2009
44	Cognitive Dysfunction 01/2022 - 01/2014
34	Dementia (Dementias) 08/2022 - 01/2014
22	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2022 - 12/2012
17	Atrophy 12/2021 - 04/2012
12	Tauopathies 06/2022 - 10/2014
12	Stroke (Strokes) 01/2022 - 07/2014
11	Inflammation (Inflammations) 12/2020 - 02/2011
10	Hypertension (High Blood Pressure) 01/2022 - 10/2013
10	Disease Progression 12/2021 - 04/2012
10	Epilepsy (Aura) 05/2015 - 10/2008
9	Neuroinflammatory Diseases 12/2021 - 04/2012
8	Ischemic Stroke 12/2020 - 02/2010
6	Parkinson Disease (Parkinson's Disease) 05/2022 - 05/2014
6	Pathologic Constriction (Stenosis) 04/2020 - 01/2019
6	Seizures (Absence Seizure) 01/2015 - 10/2008
5	Infarction (Infarctions) 12/2020 - 07/2014
5	Frontotemporal Dementia (Semantic Dementia) 05/2018 - 02/2014
4	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 05/2018 - 05/2013
4	Amyloid Plaque 11/2017 - 01/2014
4	Mitochondrial Diseases (Mitochondrial Disease) 10/2017 - 11/2009
4	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 07/2017 - 02/2014
4	Neoplasms (Cancer) 05/2015 - 10/2013
3	Obesity 01/2022 - 11/2020
3	Pathologic Processes 01/2022 - 01/2016
3	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2018 - 01/2016
3	Genetic Predisposition to Disease (Genetic Predisposition) 01/2017 - 01/2014
3	Nervous System Diseases (Neurological Disorders) 07/2016 - 10/2014
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 08/2015 - 07/2014
2	Diabetes Mellitus 11/2021 - 01/2019
2	Orthostatic Hypotension (Postural Hypotension) 08/2021 - 11/2020
2	Hallucinations (Hallucination) 08/2021 - 01/2018
2	Amyloidosis 01/2021 - 01/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2021 - 07/2014
2	Hyperuricemia 01/2021 - 11/2019
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 11/2020 - 10/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2020 - 01/2018
2	Hyperlipidemias (Hyperlipidemia) 01/2020 - 11/2019
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2019 - 01/2019
2	Dyslipidemias (Dyslipidemia) 01/2019 - 10/2013
2	Necrosis 01/2019 - 11/2009
2	Corticobasal Degeneration 05/2018 - 07/2017
2	Brain Ischemia (Cerebral Ischemia) 08/2015 - 02/2015

Drug/Important Bio-Agent (IBA)

71	Biomarkers (Surrogate Marker)IBA 08/2022 - 01/2013
46	Amyloid (Amyloid Fibrils)IBA 01/2022 - 02/2011
21	Proteins (Proteins, Gene)FDA Link 06/2022 - 08/2013
13	Pharmaceutical PreparationsIBA 06/2022 - 10/2008
13	tau Proteins (tau Protein)IBA 06/2022 - 05/2013
13	Apolipoproteins E (ApoE)IBA 11/2021 - 04/2012
13	ApolipoproteinsIBA 01/2021 - 08/2013
12	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 07/2012
11	Amyloid beta-PeptidesIBA 01/2020 - 11/2009
11	MicroRNAs (MicroRNA)IBA 01/2017 - 01/2013
9	Peptides (Polypeptides)IBA 01/2019 - 02/2013
7	ClusterinIBA 01/2016 - 10/2010
6	Biological ProductsIBA 08/2022 - 05/2016
6	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 06/2022 - 05/2011
6	CytokinesIBA 01/2016 - 02/2009
4	SynucleinsIBA 05/2022 - 11/2014
4	InflammasomesIBA 01/2015 - 12/2013
3	Complement System Proteins (Complement)IBA 01/2022 - 08/2010
3	CholesterolIBA 01/2022 - 01/2015
3	NeurograninIBA 01/2022 - 01/2020
3	CalciumIBA 06/2021 - 11/2009
3	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 01/2020
3	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2020 - 01/2019
3	ProgranulinsIBA 10/2020 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 08/2015
3	Memantine (Namenda)FDA Link 12/2018 - 01/2014
3	Carrier Proteins (Binding Protein)IBA 01/2017 - 02/2011
3	Phospholipases (Phospholipase)IBA 01/2016 - 01/2015
3	Vesicular Transport Adaptor ProteinsIBA 01/2016 - 04/2014
3	Phosphotransferases (Kinase)IBA 01/2016 - 10/2014
3	Toll-Like Receptor 2IBA 10/2011 - 02/2011
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 08/2022 - 11/2016
2	EnzymesIBA 06/2022 - 01/2014
2	ProteomeIBA 01/2022 - 10/2021
2	TeaIBA 01/2022 - 01/2020
2	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2021
2	Apolipoprotein E4IBA 01/2022 - 01/2018
2	Indicators and Reagents (Reagents)IBA 01/2021 - 01/2021
2	Uric Acid (Urate)IBA 01/2021 - 04/2020
2	LipidsIBA 01/2021 - 01/2020
2	Glycoproteins (Glycoprotein)IBA 10/2020 - 04/2015
2	Apolipoproteins B (ApoB)IBA 10/2020 - 01/2019
2	C-Reactive ProteinIBA 02/2020 - 01/2019
2	Blood Glucose (Blood Sugar)IBA 01/2020 - 12/2019
2	Adenosine Triphosphate (ATP)IBA 12/2019 - 01/2015
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 12/2019 - 11/2019
2	Insulin (Novolin)FDA Link 11/2019 - 01/2016
2	Interleukin-10 (Interleukin 10)IBA 01/2019 - 01/2016
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 01/2019
2	Nerve Growth Factor (NGF)IBA 01/2019 - 01/2018
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019 - 12/2015
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 12/2018 - 02/2015
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2016 - 04/2015
2	Antipsychotic Agents (Antipsychotics)IBA 01/2016 - 01/2015
2	InterleukinsIBA 08/2015 - 09/2014
2	Metformin (Glucophage)FDA LinkGeneric 08/2015 - 07/2014

Therapy/Procedure

25	Therapeutics 01/2022 - 02/2011